Long-term tenofovir and bone density in chronic hepatitis B
Checks bone density in adults with chronic hepatitis B taking tenofovir long term.
Plain-language title generated from the registry record
Registry title: Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B
Key facts
- Where
- Asyut, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06990438, who can take part
Where in Egypt
- Faculty of Medicine, AssuitAsyut, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT06990438
- Record updated
- 25 May 2025
- Original description
This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection. Tenofovir is a widely used antiviral medication for the treatment of HBV. While it is generally well tolerated, some studies have reported potential adverse effects on bone mineral density, particularly with long-term use.Read full original descriptionShow less
Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B
This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection. Tenofovir is a widely used antiviral medication for the treatment of HBV. While it is generally well tolerated, some studies have reported potential adverse effects on bone mineral density, particularly with long-term use.
The objective of this research is to assess whether extended TDF therapy is associated with reduced bone density or increased risk of osteopenia or osteoporosis in adult patients with chronic HBV infection. The study will involve clinical evaluation and radiological assessment of bone health using dual-energy X-ray absorptiometry (DEXA) scans, as well as relevant biochemical markers.
This investigation will provide important data on the long-term safety profile of Tenofovir in relation to bone health and help guide future clinical decisions for the management of chronic hepatitis B.
Inclusion: -; Adult male or female patients aged 18 to 60 years; Diagnosed as HBV-positive; Long-term use of Tenofovir Disoproxil Fumarate (TDF) for more than five years.
Exclusion: Patients on combination therapy, including:; Interferon and Nucleoside analogue combination therapy; Multiple nucleoside analogue combination therapy; Presence of other chronic liver diseases; Diagnosed with Chronic Kidney Disease (CKD), regardless of etiology; Patients who refuse to participate in the study; -.